Purpose: To investigate the impact of multiparametric MRI (mpMRI) on risk group assessment of patients with prostate cancer (PCa) initially addressed to External Beam Radiation Therapy (EBRT). Materials and Methods: we prospectively performed mpMRI (3.0Tsystem) in 44 patients addressed to EBRT, using a multiparametric protocol (high-resolution multiplanar T2-weighted, Diffusion-weighted and dynamic contrast-enhanced imaging). Risk group was assessed in accordance with the National Comprehensive Cancer Network (NCCN) categories, by combining prostate-specific-antigen level, Gleason score and the T-stage as established by digital rectal examination (clinical risk assessment; c-RA) versus mpMRI (mpMRI-risk assessment; mpMRI-RA). The agreement between c-RA and mpMRI-RA was investigated using Cohen’s kappa. Results: Patients were included in very low/low risk, intermediate risk, high risk, very high risk and metastatic NCCN categories in 10 (22.7%), 18 (40.9%), 15 (34.1%), 1 (2.3%) and 0 cases using c-RA vs. 8 (18.2%), 14 (31.8%), 14 (31.8%), 4 (9.1%) and 4 (9.1%) cases using mpMRI-RA, respectively, with only moderate agreement (k = 0.43). MpMRI-RA determined risk downgrading in 2/44 patients (4.5%), and risk upgrading in 16/44 patients (36.3%). After mpMRI, EBRT remained indicated in all patients. Conclusion: mpMRI changed clinical risk stratification in about 41% of patients with PCa, with potential impact on EBRT planning.
Impact of multiparametric magnetic resonance imaging on risk group assessment of patients with prostate cancer addressed to external beam radiation therapy
ZUIANI, Chiara;GIROMETTI, Rossano
2016-01-01
Abstract
Purpose: To investigate the impact of multiparametric MRI (mpMRI) on risk group assessment of patients with prostate cancer (PCa) initially addressed to External Beam Radiation Therapy (EBRT). Materials and Methods: we prospectively performed mpMRI (3.0Tsystem) in 44 patients addressed to EBRT, using a multiparametric protocol (high-resolution multiplanar T2-weighted, Diffusion-weighted and dynamic contrast-enhanced imaging). Risk group was assessed in accordance with the National Comprehensive Cancer Network (NCCN) categories, by combining prostate-specific-antigen level, Gleason score and the T-stage as established by digital rectal examination (clinical risk assessment; c-RA) versus mpMRI (mpMRI-risk assessment; mpMRI-RA). The agreement between c-RA and mpMRI-RA was investigated using Cohen’s kappa. Results: Patients were included in very low/low risk, intermediate risk, high risk, very high risk and metastatic NCCN categories in 10 (22.7%), 18 (40.9%), 15 (34.1%), 1 (2.3%) and 0 cases using c-RA vs. 8 (18.2%), 14 (31.8%), 14 (31.8%), 4 (9.1%) and 4 (9.1%) cases using mpMRI-RA, respectively, with only moderate agreement (k = 0.43). MpMRI-RA determined risk downgrading in 2/44 patients (4.5%), and risk upgrading in 16/44 patients (36.3%). After mpMRI, EBRT remained indicated in all patients. Conclusion: mpMRI changed clinical risk stratification in about 41% of patients with PCa, with potential impact on EBRT planning.File | Dimensione | Formato | |
---|---|---|---|
EJR-D-15-01282R1.pdf
non disponibili
Tipologia:
Documento in Pre-print
Licenza:
Non pubblico
Dimensione
1.52 MB
Formato
Adobe PDF
|
1.52 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.